Brigatinib (AP26113)

Catalog No.S8229

Brigatinib (AP26113) Chemical Structure

Molecular Weight(MW): 584.09

Brigatinib (AP26113) is a potent and selective ALK (IC50, 0.6 nM) and ROS1 (IC50, 0.9 nM) inhibitor. It also inhibits ROS1, FLT3, and mutant variants of FLT3 (D835Y) and EGFR with lower potentcy.

Size Price Stock Quantity  
USD 97 In stock
USD 297 In stock
USD 677 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 5 Publications

1 Customer Review

  • Immunoblotting analysis of H3122 and H3122-CER cells showing that brigatinib did not inhibit EGFR phosphorylation (p-EGFR). Total EGFR (t-EGFR) is also shown. Actin was used as a loading control. The cells were treated with brigatinib for 2 hours.

    Mol Cancer Res, 2017, 15(1):106-114. Brigatinib (AP26113) purchased from Selleck.

Purity & Quality Control

Choose Selective ALK Inhibitors

Biological Activity

Description Brigatinib (AP26113) is a potent and selective ALK (IC50, 0.6 nM) and ROS1 (IC50, 0.9 nM) inhibitor. It also inhibits ROS1, FLT3, and mutant variants of FLT3 (D835Y) and EGFR with lower potentcy.
Targets
ALK [1]
(Cell-free assay)
ROS1 [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
IGF1R [1]
(Cell-free assay)
EGFR(C797S/del19) [2]
(cell-based)
0.37 nM 1.9 nM 2.1 nM 24.9 nM 39.9 nM
In vitro

Beyond ALK, IGF1R, and InsR, brigatinib also potently inhibits FLT3 and ROS1 with IC50 values of 2.1 and 1.9 nM, respectively. It does not show significant activity toward c-Met or Ron up to 1 μM[1]. Brigatinib overcomes the resistance of EGFR-triple-mutant and the activity depends on ATP-competitive manner with less affection to wild-type EGFR[2].

Assay
Methods Test Index PMID
Western blot
pEGFR / EGFR / pAkt / Akt / pERK / ERK / pS6 / S6; 

PubMed: 28287083     


Ba/F3 cells expressing T790M/del19 (d) or C797S/T790M/del19 (e) were treated with the indicated concentrations of brigatinib, AP26113 analog, TAE684, ceritinib or ASP3026 for 6 h. Phosphorylation of EGFR and its downstream signals were evaluated by wester䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 

pALK / ALK; 

PubMed: 21502504     


Suppression of ALK signaling by AP26113 in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of AP26113 for 6 h. Cell lysates were immunoblotted to detect the indicated proteins.

pROS1 / ROS1 / pSTAT3 / STAT3 ; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated䲧疝Ỵ疞㧀

28287083 21502504 25351743
Growth inhibition assay
Cell viability ; 

PubMed: 25351743     


(A) Ba/F3 cells expressing CD74-ROS1 (clone #6) were seeded in 96 well-plates and treated with indicated concentration of crizotinib, ceritinib, AP26113, ASP3026, or alectinib for 72 h. Cell viability was analyzed using the CellTiter-Glo assay. (B) IC50 v䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€𢡄⟼෕€䀷痗⟼෕౴⟼෕㵶痗⟼෕뺖᎒泌Itemセ᎒Count﫨呂⠬෕猴፲⟼෕፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄堚ў齃礤v�堞ﻮ᎒猢

25351743
In vivo Mouse PK parameters for Brigatinib following oral dosing (10 mg/kg): Cmax=448 ng/mL,t1/2=5.8 h. And in CD rats, after dosing at 3 mg/kg i.v, CL=0.46 L/(h·kg), t1/2=4.8 h, Vss=7.8 L/kg; Dosed at 10 mg/kg p.o, Cmax=305 ng/mL, tmax=4 h, t1/2=3.4 h, F%=52. Brigatinib demonstrates dose-dependent antitumor activity[1]. Brigatinib demonstrates growth inhibition activity in PC9 triple-mutant xenograft model and in combination with anti-EGFR antibody to potentiate the efficacy both in vitro and in vivo as shown in first-generation EGFR-TKI-resistant patients[2].

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: U937 cells, Karpas-299 cells, H3122 cells
  • Concentrations: --
  • Incubation Time: 72 h
  • Method:

    All cell lines were used within 20 passages of the initial thaw. Following inhibitor treatment for 72 h, cell growth was assessed to determine the concentration that causes 50% inhibition of cell viability (IC50).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: female CD rats
  • Formulation: --
  • Dosages: 10 mg/kg(p.o); 2 mg/kg(i.v)
  • Administration: p.o, i.v
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 43 mg/mL warmed (73.61 mM)
DMSO 1 mg/mL warmed (1.71 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 584.09
Formula

C29H39ClN7O2P

CAS No. 1197953-54-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) April 1 2019 Phase 2
NCT03737994 Not yet recruiting ALK Gene Rearrangement|ALK Positive|Lung Non-Squamous Non-Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8 National Cancer Institute (NCI) April 1 2019 Phase 2
NCT03868423 Not yet recruiting Advanced Malignant Neoplasm|ALK Fusion Protein Expression|ALK Gene Amplification|ALK Gene Mutation|Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Neoplasm in the Central Nervous System|Metastatic Malignant Solid Neoplasm|ROS1 Fusion Positive|ROS1 Gene Amplification|ROS1 Gene Mutation Sameek Roychowdhury|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center March 31 2019 Phase 2
NCT03420742 Not yet recruiting Carcinoma Advanced ALK+ or ROS1+Non-Small-Cell Lung Neoplasm Advanced ALK+ or ROS1+Solid Tumors Ariad Pharmaceuticals|Takeda March 28 2019 Phase 1
NCT03868423 Not yet recruiting Advanced Malignant Neoplasm|ALK Fusion Protein Expression|ALK Gene Amplification|ALK Gene Mutation|Locally Advanced Malignant Solid Neoplasm|Metastatic Malignant Neoplasm in the Brain|Metastatic Malignant Neoplasm in the Central Nervous System|Metastatic Malignant Solid Neoplasm|ROS1 Fusion Positive|ROS1 Gene Amplification|ROS1 Gene Mutation Sameek Roychowdhury|National Cancer Institute (NCI)|Ohio State University Comprehensive Cancer Center March 31 2019 Phase 2
NCT03420742 Not yet recruiting Carcinoma Advanced ALK+ or ROS1+Non-Small-Cell Lung Neoplasm Advanced ALK+ or ROS1+Solid Tumors Ariad Pharmaceuticals|Takeda March 28 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ALK Signaling Pathway Map

Related ALK Products0

Tags: buy Brigatinib (AP26113) | Brigatinib (AP26113) supplier | purchase Brigatinib (AP26113) | Brigatinib (AP26113) cost | Brigatinib (AP26113) manufacturer | order Brigatinib (AP26113) | Brigatinib (AP26113) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID